Skip to main content
TipRanks
Go Ultimate75% OFF

Oncolys BioPharma, Inc. (4588) AI Stock Analysis

1 Followers
JP:4588

Oncolys BioPharma, Inc.

(TSE/TYO:4588)

Select Model
Rating:51Neutral
Price Target:JPY 8,452.00â–²(0.50% Upside)
Action:reiterated
Date:09/19/26

The overall score is 51, reflecting a sharp divide between strong market momentum and weak fundamentals. The stock's price is surging based on technical strength, but this is not supported by financials, as the company has minimal revenue, large losses, and a high cash burn rate. The negative P/E ratio further underscores the lack of current earnings. The primary risk is that the positive technical trend reverses if the company's financial position does not improve.

Positive Factors
Manageable LeverageDebt remains modest relative to equity, reducing balance-sheet strain compared with a highly leveraged biotech. This gives Oncolys greater flexibility to support development activities and absorb operating volatility, although continued losses could gradually weaken that position.
Negative Factors
Revenue CollapseThe sharp multi-year revenue decline demonstrates substantial deterioration in the company’s current commercial base. Persistently low revenue limits internal funding for drug development and makes future financial performance highly dependent on a major product, licensing, or partnership-driven revenue inflection.

Oncolys BioPharma, Inc. (4588) vs. iShares MSCI Japan ETF (EWJ)

-200%0%200%400%600%800%JP:4588+708.65%EWJ+16.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 247.60B
Dividend Yield
―
Average Volume (3M)
1.75M
Price to Earnings (P/E)
-146.1
Beta (1Y)
1.96
Revenue Growth
1748.97%
EPS Growth
35.11%
Country
Japan
Employees
42
Sector
General
Sector Strength
55
Industry
Biotechnology

Oncolys BioPharma, Inc. Business Overview & Revenue Model

Company Description

Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the Unit...

How the Company Makes Money

Detailed, company-specific revenue breakdown (e.g., product sales by drug, recurring service revenue, or disclosed milestone/royalty structures) is not available in the information provided here; therefore, this data point is null.

Oncolys BioPharma, Inc. Financial Statement Overview

Summary

Financial performance is critically weak. Revenue has collapsed to near zero (JPY 28.5M) with large net losses (JPY 2.1B). Operating cash flow is deeply negative, burning ~JPY 1.9B annually. The only support is a solid balance sheet with JPY 4.0B in equity and low debt, but this is being rapidly depleted.

Income Statement

10Very Negative

Balance Sheet

60Neutral

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue28.55M28.55M31.38M63.04M976.18M642.49M
Gross Profit28.30M28.30M31.38M30.61M338.49M198.80M
EBITDA-2.05B-2.05B-1.68B-1.93B-1.14B-1.60B
Net Income-2.06B-2.06B-1.68B-1.94B-1.15B-1.62B
Balance Sheet
Total Assets4.56B4.56B3.20B2.04B2.65B4.29B
Cash, Cash Equivalents and Short-Term Investments3.72B3.72B2.41B1.53B1.71B3.45B
Total Debt320.02M320.02M324.64M315.17M393.66M503.47M
Total Liabilities555.91M555.91M446.65M566.50M491.69M697.88M
Stockholders Equity4.00B4.00B2.75B1.47B2.16B3.59B
Cash Flow
Free Cash Flow0-1.94B-2.02B-1.34B-1.72B-1.74B
Operating Cash Flow0-1.94B-2.02B-1.34B-1.72B-1.74B
Investing Cash Flow0-7.58M-4.71M-5.39M20.12M-942.00K
Financing Cash Flow03.22B2.88B1.14B-113.83M3.09B

Oncolys BioPharma, Inc. Technical Analysis

Technical Analysis SentimentPositive
Last Price8410.00

Price Trends

50DMA6174.20Positive
100DMA4540.00Positive
200DMA3521.32Positive

Market Momentum

MACD589.20Negative
RSI65.28Neutral
STOCH70.29Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Positive. The current price of 8410.00 is above the 20-day moving average (MA) of 6932.00, above the 50-day MA of 6174.20, and above the 200-day MA of 3521.32, indicating a bullish trend. The MACD of 589.20 indicates Negative momentum. The RSI at 65.28 is Neutral, neither overbought nor oversold. The STOCH value of 70.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4588.

Oncolys BioPharma, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:4588 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:4588JP:458851NeutralJPY 248.42B-146.15――1748.97%35.11%
JP:4583JP:458349NeutralJPY 6.30B-6.28――-13.40%7.50%
JP:4587JP:458748NeutralJPY 138.26B-47.73-5.85%―14.25%50.07%
JP:4564JP:456441NeutralJPY 6.53B-6.96-42.81%―-25.56%17.01%
JP:4575JP:457539UnderperformJPY 13.94B-10.04―――-12.48%

* General Sector Average

Performance Comparison

0%200%400%600%JP:4588JP:4587JP:4564JP:4575JP:4583Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4588 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4588Oncolys BioPharma, Inc.8410.007342.00687.45%
JP:4587Peptidream 1065.00-518.50-32.74%
JP:4564OncoTherapy Science, Inc.16.00-7.00-30.43%
JP:4575CanBas Co., Ltd.705.00-84.00-10.65%
JP:4583Chiome Bioscience Inc.77.00-46.00-37.40%

Oncolys BioPharma, Inc. Corporate Events

Oncolys BioPharma Reports Higher Sales and Narrower Nine-Month Loss

Nov 6, 2026

Oncolys BioPharma reported net sales of ¥527 million for the nine months ended September 30, 2026, up from ¥28 million a year earlier. Operating loss narrowed to ¥1.104 billion from ¥1.571 billion, while net loss improved to ¥1.115 billion from ¥1.61...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 19, 2026